TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07806175: A Multicenter Phase I/II Clinical Study to Evaluate the Safety and Efficacy of RCZY690 Tablets in Patients With Locally Advanced Unresectable or Metastatic Malignant Solid Tumors

Sponsor: Rongchang Pharmaceuticals Co., Ltd. · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 486 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$12,566,400

Rescue Site Savings

+$8,285,970

Unlock Full NCT07806175 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07806175 Rescue Dossier →